Interpace Q2 revenue $11.0M (+49% YoY); net income $0.4M vs loss

INTERPACE BIOSCIENCES, INC.

2023-Q2 EPS reported $0.12 revenue$20,853,000

Q2 net revenue $11.0M, up 49% YoY; gross margin improved to 62% from 52%.
Income from continuing operations $0.4M vs loss of $2.1M in Q2 2022.
Adjusted EBITDA $1.3M vs $(1.6)M loss; cash collections $10.2M, up 23% YoY.
Test volume up 15% YoY; cash balance increased to $5.1M from $1.9M.
Company faces Novitas LCD challenge for PancraGEN test; expects resolution in months to year.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

INTERPACE BIOSCIENCES, INC. reported second quarter ended June 30, 2023 results: revenue Net Revenue was $11.0 million, net income Income from continuing operations was $0.4 million.

Period: second quarter ended June 30, 2023
Revenue: Net Revenue was $11.0 million
Net income: Income from continuing operations was $0.4 million
Result: reported results

Exact text from the filing

Second quarter Net Revenue was $11.0 million, a $3.6 million increase over second quarter 2022. Income from continuing operations in the second quarter of 2023 was $0.4 million, an improvement of $2.5 million from the prior year quarter's loss of $2.1 million.

View on SEC.gov

Browse all earnings releases →

INTERPACE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-027331

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.